Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;42(3):703-709.
doi: 10.1007/s10067-022-06404-8. Epub 2022 Oct 29.

Analysis of the clinical features of antisynthetase syndrome: a retrospective cohort study in China

Affiliations

Analysis of the clinical features of antisynthetase syndrome: a retrospective cohort study in China

Ruoming Wang et al. Clin Rheumatol. 2023 Mar.

Abstract

Objective: To summarize the clinical, serological, and radiological characteristics of anti-synthetase syndrome (ASS) patients with different anti-aminoacyl-tRNA synthase antibody.

Methods: Retrospective analysis was performed based on the clinical data of 88 patients diagnosed with ASS in Tianjin Medical University General Hospital from January 2015 to December 2020. The clinical data included general conditions, serological indexes, high-resolution CT (HRCT) characteristics, and pulmonary function manifestations.

Results: Among the 88 patients, there were 17 males and 71 females. The anti-synthetase antibodies included anti-Jo-1 (n = 42), anti-PL-7 (n = 14), anti-PL-12 (n = 9), anti-EJ (n = 20), and anti-OJ (n = 3) antibodies. The most common clinical manifestations of ASS patients were interstitial lung disease (ILD) (90%, 79/88), followed by myositis (79.5%, 70/88), arthritis (50%, 44/88), and rash (50%, 44/88). The frequency of arthritis in the anti-Jo-1 antibody-positive group was higher than that of the anti-PL-7 and anti-EJ antibody groups (P = 0.004, P = 0.002, respectively). The frequency of Gottron's sign in the anti-PL-7 antibody positive group was higher than that of the anti-Jo-1 and anti-PL-12 antibody-positive groups (P = 0.006, P = 0.04). Isolated arthritis was the most frequent initial symptoms in anti-Jo-1 antibody-positive group (47.6%, 20/42), while isolated ILD was most frequent in patients with anti-EJ antibody (50%, 10/20), and isolated myositis in patients carrying anti-OJ (66.7%, 2/3). There were only 32 cases (36.4%) with the typical clinical triad (myositis, arthritis, ILD). In our cohort, 79 patients (90%) were complicated with ILD. Meanwhile, 7 out of 79 cases were classified into rapid progressive group with 6 cases (85.7%) carrying anti-Ro-52 antibody. The probability of reticular and honeycombing shadow in HRCT of patients with anti-EJ antibody positive was higher than that of other groups (P < 0.05).

Conclusion: ILD, myositis, and arthritis were the most common clinical manifestations in patients with ASS. Different antibody-positive patients have different initial symptoms. Patients with isolated arthritis, myositis, and ILD should be vigilant of ASS. The complication of anti-Ro-52 antibody in ASS patients was associated with rapidly progressive pulmonary interstitial disease. Patients with positive anti-EJ antibodies tend to have ILD as the first symptom, and with high occurrence of ILD, the HRCT showed more serious patterns, suggesting the correlation between anti-EJ antibodies and ILD. Key Points • Analyzing specific clinical manifestations in ASS patients with different ARS antibodies can raise awareness of the disease and reduce misdiagnosis. • Anti-EJ antibodies were correlated with ILD. • Anti-Ro-52 antibodies may correlate with RP-ILD in ASS patients.

Keywords: Anti-Ro-52 antibody; Anti-synthetase syndrome; Interstitial lung disease.

PubMed Disclaimer

References

    1. Mahler M, Miller F, Fritzler M (2014) Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review [J]. Autoimmunity Rev 13(0):367–371
    1. Imbert-Masseau A, Hamidou M, Agard C et al (2003) Antisynthetase syndrome [J]. Joint Bone Spine 70(3):161–168 - DOI - PubMed
    1. Satoh M, Tanaka S, Ceribelli A et al (2017) A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy [J]. Clin Rev Allergy Immunol 52(1):11–19 - DOI
    1. McHugh N, Tansley S (2018) Autoantibodies in myositis [J]. Nat Rev Rheumatol 14(5):290–302 - DOI - PubMed
    1. Witt L, Curran J, Strek M (2016) The diagnosis and treatment of antisynthetase syndrome [J]. Clin Pulm Med 23(5):218–226 - DOI - PubMed - PMC

Supplementary concepts

LinkOut - more resources